Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib Monotherapy in Relapsed/Refractory AML
NCT00989261Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2009
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd.. Started Nov 2009; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00989261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00989261.